furosemide / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   79 Trials   79 Trials   6783 News 


«12...2627282930313233343536...8687»
  • ||||||||||  vancomycin / Generic mfg., furosemide / Generic mfg.
    NEPHROTOXIC MEDICATION EXPOSURES IN CRITICALLY ILL CHILDREN WITH SEPSIS ([VIRTUAL]) -  Mar 23, 2022 - Abstract #SCCM2022SCCM_2509;    
    Simultaneous exposure to ≥3 NTMs is a known risk factor for AKI, and 85% of the cohort had this risk factor. The rate of AKI and death in this cohort is similar to previously described cohorts of critically ill children with sepsis.
  • ||||||||||  NEPHROTOXIC MEDICATION EXPOSURE IN CHILDREN ON CONTINUOUS RENAL REPLACEMENT THERAPY ([VIRTUAL]) -  Mar 23, 2022 - Abstract #SCCM2022SCCM_2378;    
    While common and largely driven by diuretic and antimicrobials, NTX exposures PRE CRRT or during CRRT were not associated with MAKE-60 in pediatric patients. Outcome associations in different vulnerable groups, such as oncology and transplant need to be further explored to provide insight into potentially actionable modifiable exposure risk.
  • ||||||||||  furosemide / Generic mfg.
    RELATIONSHIP BETWEEN MEAN ARTERIAL PRESSURE AND FUROSEMIDE STRESS TEST SUCCESS RATES ([VIRTUAL]) -  Mar 23, 2022 - Abstract #SCCM2022SCCM_2368;    
    In patients with a MAP ≥ 75 mmHg, 60 out of 104 (57.7%) had a successful FST compared to 28 out of 121 (23.1%) of patients who had a MAP < 75 mmHg ( p < 0.0001). Patients on vasopressors at the time of the furosemide dose had lower rates of success compared to those not on vasoactive agents (30.4% vs 68.2%, p = 0.026).
  • ||||||||||  furosemide / Generic mfg.
    Trial completion date, Trial primary completion date:  Spectral Analysis of Central Venous Pressure Waveform (clinicaltrials.gov) -  Mar 22, 2022   
    P=N/A,  N=60, Recruiting, 
    Patients on vasopressors at the time of the furosemide dose had lower rates of success compared to those not on vasoactive agents (30.4% vs 68.2%, p = 0.026). Trial completion date: May 2022 --> Feb 2024 | Trial primary completion date: May 2022 --> Feb 2024
  • ||||||||||  furosemide / Generic mfg.
    Journal:  Alternative to animal experimentation in pharmacology teaching: Development and validation of an equivalent digital learning tool. (Pubmed Central) -  Mar 17, 2022   
    The participants were randomly assigned to groups of traditional or digital teaching methods, with the common theme of the class being the effect of a diuretic agent (furosemide) in rats...It found the two teaching methods (digital and traditional) to be equivalent in terms of motivation and knowledge acquisition. In our study, digital pedagogical tools as an alternative to live animals did not affect students' motivation and knowledge acquisition.
  • ||||||||||  furosemide / Generic mfg.
    Journal:  Kidney Injury Causes Accumulation of Renal Sodium That Modulates Renal Lymphatic Dynamics. (Pubmed Central) -  Mar 15, 2022   
    High sodium within the renal interstitium following proteinuric injury is associated with impaired renal lymphatic pumping that may, in part, involve the SPAK-NKCC1-eNOS pathway, which may contribute to sodium retention and reduce lymphatic responsiveness to furosemide. We propose that this lymphatic vessel dysfunction is a novel mechanism of impaired interstitial clearance and edema in proteinuric kidney disease.
  • ||||||||||  furosemide / Generic mfg.
    Prognostic associations of loop diuretics trajectories in dilated cardiomyopathy (ePoster station 4) -  Mar 12, 2022 - Abstract #HEARTFAILURE2022HEART_FAILURE_885;    
    908 DCM patients with information on furosemide equivalent dose (FED) atbaseline and within 24 months were enrolled...In a large DCM cohort with longitudinal data, loop diuretics trajectories were stronglyassociated with mortality/morbidity. Lower doses or withdrawal of loop diuretics should besystematically perceived as being associated with improved outcome.
  • ||||||||||  furosemide / Generic mfg.
    Patients with heart failure receiving SGLT2 inhibitors : do they need the same dose of furosemide? (ePoster station 2) -  Mar 12, 2022 - Abstract #HEARTFAILURE2022HEART_FAILURE_794;    
    We recorded basic demographic parameters (age, sex), heart failure classification based on ESC current guidelines [heart failure with reduced ejection fraction-(HFrEF) vs heart failure with preserved ejection fraction (HFpEF) vs heart failure with mildly reduced ejection fraction(HFmrEF)], which SGLT2i they received (dapagliflozin vs empagliflozin), as well as the renal function (estimated by CKD-EPI GFR calculation).Finally, we recorded any changes made in the furosemide dosage these patients received. As most of the patients with HF nowadays also receive treatment with SGLTi, physicians dealing with these patients should take into consideration the possible need to reduce furosemide dose, in order to succeed the euvolemic status and offer them the best medical treatment.
  • ||||||||||  Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
    The effects on empagliflozin on diuretics reduction in outpatient heart failure patients (ePoster station 3) -  Mar 12, 2022 - Abstract #HEARTFAILURE2022HEART_FAILURE_760;    
    Among outpatient HF patients treated with both diuretics and empagliflozin, 20.3% of patients showed a reduction in their diuretic dose. This suggests that SGLT2i has the clinical benefits in outpatient HF patients.
  • ||||||||||  furosemide / Generic mfg.
    The use of loop diuretics in patients with chronic heart failure; an observational overview (ePoster station 3) -  Mar 12, 2022 - Abstract #HEARTFAILURE2022HEART_FAILURE_740;    
    Conclusion In this large registry of real-world HF patients, loop-diuretic use was highest among HFrEF patients. NYHA class III & IV and diabetes mellitus were significantly associated with a furosemide dose equivalent >80mg, regardless of LVEF.
  • ||||||||||  furosemide / Generic mfg.
    Long-term progression of subclinical pulmonary congestion by lung ultrasound in outpatients with heart failure (ePoster station 1) -  Mar 12, 2022 - Abstract #HEARTFAILURE2022HEART_FAILURE_487;    
    The number of patients on loop diuretics was significantly lower in LUS 2 than in LUS 1 (p=0.02), while the furosemide-equivalent doses of those patients remaining on diuretics was not significantly different (p=0.14)... In stable chronic HF outpatients no increase in subclinical lung congestion was observed despite loop diuretic reduction and functional class worsening in some patients.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Safety and effectiveness of Sacubitril-Valsartan in a real-world population. (ePoster station 2) -  Mar 12, 2022 - Abstract #HEARTFAILURE2022HEART_FAILURE_463;    
    SV was well tolerated and uptitration to the maximal TD was possible in 57,8%. In our real-world cohort, with heterogeneous patients, with more comorbidities and many who did not tolerate TD, the overall outcomes rates were similar when compared to PARADIGM-HF.
  • ||||||||||  furosemide / Generic mfg.
    No harmful effect of diuretic down-titration on pulmonary congestion when introducing sodium-glucose cotransporter 2 inhibitors (ePoster station 3) -  Mar 12, 2022 - Abstract #HEARTFAILURE2022HEART_FAILURE_411;    
    The number of patients treated with loop diuretics decreased from 66 to 33 (p<0.001) and the mean dose of furosemide (or equivalent) in those who continued decreased from 61±5 mg/day to 45.8±20 mg/day (p <0.001)... The introduction of SGLT2i allowed a significant reduction of diuretics in chronic HF patients and diabetes, without evidence of worsening lung congestion assessed neither by LUS nor by HF biomarkers.
  • ||||||||||  furosemide / Generic mfg., spironolactone / Generic mfg.
    Frailty in patients with acute heart failure (ePoster station 4) -  Mar 12, 2022 - Abstract #HEARTFAILURE2022HEART_FAILURE_68;    
    However, mean furosemide dose at discharge was higher in frail P (60±41 mg vs 49±20 mg-p=0.06)... In patients with acute heart failure, frailty is frequent and is associated with higher degrees of congestion, longer hospitalization and more events after discharge.
  • ||||||||||  furosemide / Generic mfg.
    Door-to-furosemide time in acute heart failure (ePoster station 4) -  Mar 12, 2022 - Abstract #HEARTFAILURE2022HEART_FAILURE_57;    
    Less than half of patients received intravenous furosemide within 1 hour after admission. In-hospital mortality did not differ between patients who received early treatment with furosemide versus those who received a delayed treatment.
  • ||||||||||  ceftriaxone / Generic mfg., amoxicillin / Generic mfg.
    Observational data, Journal:  Drug utilization study in neonatal intensive care unit at tertiary care hospital. (Pubmed Central) -  Mar 11, 2022   
    Premature birth and resulting low birth weight were the main reasons for drug prescription. High administration of antibiotics is probably an area of concern and should be seriously considered.
  • ||||||||||  Henletor (torsemide) / Orchid
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure (clinicaltrials.gov) -  Mar 9, 2022   
    P3,  N=2859, Active, not recruiting, 
    High administration of antibiotics is probably an area of concern and should be seriously considered. Recruiting --> Active, not recruiting | N=6000 --> 2859 | Trial completion date: Aug 2023 --> Apr 2022 | Trial primary completion date: Aug 2023 --> Apr 2022
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal:  Coronavirus disease 2019 on routine testing in eclampsia: a case report. (Pubmed Central) -  Mar 9, 2022   
    Recruiting --> Active, not recruiting | N=6000 --> 2859 | Trial completion date: Aug 2023 --> Apr 2022 | Trial primary completion date: Aug 2023 --> Apr 2022 A diagnosis of preeclampsia or eclampsia should prompt testing for coronavirus disease 2019.
  • ||||||||||  Actimab-A (lintuzumab-Ac225) / Actinium
    Trial completion, Enrollment change:  Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients (clinicaltrials.gov) -  Mar 9, 2022   
    P1/2,  N=40, Completed, 
    Recruiting --> Completed Active, not recruiting --> Completed | N=72 --> 40
  • ||||||||||  furosemide / Generic mfg.
    Trial completion date, Trial primary completion date:  PURE: Peritoneal Ultrafiltration in Cardio Renal Syndrome. (clinicaltrials.gov) -  Mar 9, 2022   
    P1/2,  N=84, Not yet recruiting, 
    Active, not recruiting --> Completed | N=72 --> 40 Trial completion date: Oct 2022 --> Oct 2023 | Trial primary completion date: Sep 2022 --> Jul 2023
  • ||||||||||  Journal:  Postoperative hyperthermia-induced multiple organ failure in a child with Down syndrome: a case report. (Pubmed Central) -  Mar 8, 2022   
    Hyperthermia, together with the immune-system disorders associated with Down syndrome, may have induced hypercytokinemia and multiple organ failure. This rare case of noninfectious postoperative hyperthermia leading to multiple organ failure may help to shed further light on the currently unclear pathogenic mechanism of hyperthermia and associated multiple organ failure during the perioperative period in children.